KLTO
Klotho NeurosciencesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
KLTO Profile
Klotho Neurosciences, Inc.
A company focused on developing new disease-improving technologies for the treatment of neurodegenerative diseases and age-related conditions
Life Science Tools and Services
03/16/2021
04/29/2022
NASDAQ Stock Exchange
3
12-31
Common stock
13576 Walnut Street, Suite A, Omaha, NE 68144
--
Klotho Neurosciences, Inc., was incorporated in Delaware on March 16, 2021. The company specializes in developing patented novel disease improvement technologies, including key developments in the treatment of neurodegenerative and age-related diseases. ANEW is developing cutting-edge protein, gene and cell therapies to treat age-related pathologies such as Alzheimer's and Parkinson's diseases, ALS and rare neurodegenerative diseases. Other assets include global rights to multiple platform technologies, including a melanocortin peptide library that has been proven to regulate hunger, food intake and weight loss, and ANEW's dry nanoparticle powder injection system called Nanoject, a patented medical device for the safe and painless self-injection of insulin, GLP-1 agonists, fertility drugs and many other drugs, vaccines and protein molecules.
